title: Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.
abstract: Several cost-effectiveness models of disease-modifying treatments (DMTs) for multiple sclerosis (MS) have been developed for different populations and different countries. Vast differences in the approaches and discrepancies in the results give rise to heated discussions and limit the use of these models. Our main objective is to discuss the methodological challenges in modelling the cost effectiveness of treatments for MS. We conducted a review of published models to describe the approaches taken to date, to identify the key parameters that influence the cost effectiveness of DMTs, and to point out major areas of weakness and uncertainty. Thirty-six published models and analyses were identified. The greatest source of uncertainty is the absence of head-to-head randomized clinical trials. Modellers have used various techniques to compensate, including utilizing extension trials. The use of large observational cohorts in recent studies aids in identifying population-based, 'real-world' treatment effects. Major drivers of results include the time horizon modelled and DMT acquisition costs. Model endpoints must target either policy makers (using cost-utility analysis) or clinicians (conducting cost-effectiveness analyses). Lastly, the cost effectiveness of DMTs outside North America and Europe is currently unknown, with the lack of country-specific data as the major limiting factor. We suggest that limited data should not preclude analyses, as models may be built and updated in the future as data become available. Disclosure of modelling methods and assumptions could improve the transferability and applicability of models designed to reflect different healthcare systems.
authors: Department of Medicine, University of Rochester Medical Center, 601 Elmwood Ave, Box 648, Rochester, NY 14642, USA. joel_thompson@urmc.rochester.edu
authors: Joel P
authors: JP
authors: Thompson
authors: Amir
authors: A
authors: Abdolahi
authors: Katia
authors: K
authors: Noyes
mesh_terms: D002986:Clinical Trials as Topic / Q000379:methods; D003362:Cost-Benefit Analysis; D006801:Humans; D007155:Immunologic Factors / Q000191:economics / Q000627:therapeutic use*; D018803:Models, Economic; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000191:economics; D013997:Time Factors
chemical_list: D007155:Immunologic Factors
references: J Manag Care Pharm. 2011 Jun;17(5):377-81
references: 21657808
references: Mult Scler. 2006 Feb;12(1):24-38
references: 16459717
references: J Manag Care Pharm. 2009 Sep;15(7):543-55
references: 19739877
references: Neurology. 2002 Nov 26;59(10):1496-506
references: 12451188
references: Clin Ther. 2003 Feb;25(2):611-34
references: 12749517
references: Neurology. 2011 Jul 26;77(4):355-63
references: 21775734
references: J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):144-9
references: 10644777
references: Mult Scler. 2008 Jun;14(5):679-90
references: 18566030
references: Value Health. 2002 Jan-Feb;5(1):44-54
references: 11873383
references: Pharmacoeconomics. 2008;26(7):617-27
references: 18563952
references: Pharmacoeconomics. 2010;28(10):813-30
references: 20831289
references: Mult Scler. 2009 Jun;15(6):741-51
references: 19383645
references: Value Health. 2004 Sep-Oct;7(5):554-68
references: 15367251
references: Adv Neurol. 2006;98:125-46
references: 16400831
references: Neurology. 1998 Mar;50(3):701-8
references: 9521260
references: Neurology. 1993 Apr;43(4):655-61
references: 8469318
references: Value Health. 2011 Jul-Aug;14(5 Suppl 1):S48-50
references: 21839899
references: Health Econ. 2006 Jul;15(7):677-87
references: 16491461
references: Pharmacoeconomics. 2009;27(1):39-53
references: 19178123
references: Drugs. 2010 Sep 10;70(13):1677-91
references: 20731475
references: Pharmacoeconomics. 2010;28(11):987-93
references: 20936882
references: Value Health. 2012 Sep-Oct;15(6):796-803
references: 22999128
references: J Health Serv Res Policy. 2008 Oct;13 Suppl 3:23-30
references: 18806189
references: Value Health. 2009 Jul-Aug;12(5):657-65
references: 19508662
references: CNS Drugs. 2002;16(8):563-78
references: 12096936
references: Pharmacoeconomics. 2009;27(9):767-79
references: 19757870
references: J Health Econ. 1997 Feb;16(1):1-31
references: 10167341
references: Neurology. 2009 Sep 22;73(12):984-90
references: 19770475
references: Mult Scler. 2003 Jun;9(3):311-9
references: 12814182
references: BMJ. 2003 Mar 8;326(7388):522; discussion 522
references: 12623909
references: Rev Neurol. 2011 Aug 1;53(3):129-38
references: 21748710
references: J Manag Care Pharm. 2010 Nov-Dec;16(9):713-7
references: 21067257
references: Clin Ther. 2010 Apr;32(4):717-28
references: 20435242
references: BMJ. 1999 Dec 11;319(7224):1529-33
references: 10591710
references: Eur J Health Econ. 2003;4(1):50-9
references: 15609169
references: Farm Hosp. 2003 May-Jun;27(3):159-65
references: 12835817
references: Appl Health Econ Health Policy. 2009;7(2):91-108
references: 19731967
references: JAMA. 2012 Jul 18;308(3):247-56
references: 22797642
references: Value Health. 2009 Nov-Dec;12(8):1194-200
references: 19695009
references: J Neurol Sci. 2009 Feb 1;277 Suppl 1:S25-8
references: 19200861
references: Lancet. 1998 Nov 7;352(9139):1491-7
references: 9820296
references: J Med Econ. 2011;14(5):617-27
references: 21777161
references: N Engl J Med. 2003 Jan 2;348(1):15-23
references: 12510038
references: BMJ. 2010 Jun 03;340:c1672
references: 20522654
references: Neurology. 2001 Jun 26;56(12):1628-36
references: 11425926
references: Int J Technol Assess Health Care. 2000 Summer;16(3):768-80
references: 11028132
references: Med Decis Making. 1999 Oct-Dec;19(4):371-7
references: 10520672
references: Mult Scler. 2008 Jun;14(5):640-55
references: 18566028
references: Int J Technol Assess Health Care. 2002 Winter;18(1):127-38
references: 11987436
references: Mult Scler. 2001 Dec;7(6):349-53
references: 11795454
references: Pharmacoeconomics. 2010;28(10):889-97
references: 20831296
references: Curr Med Res Opin. 2009 Jun;25(6):1445-54
references: 19422279
references: Health Technol Assess. 1998;2(4):iii-54
references: 9580870
references: Clin Drug Investig. 2003;23(9):571-81
references: 17535070
references: Vojnosanit Pregl. 2009 Jul;66(7):556-62
references: 19678581
references: Int J Technol Assess Health Care. 2000 Summer;16(3):751-67
references: 11028131
references: Pharmacoeconomics. 2010;28(10):843-53
references: 20831292
references: Pharmacoeconomics. 2000 Jul;18(1):45-53
references: 11010603
references: Rev Neurol. 2005 Jun 16-30;40(12):705-10
references: 15973634
references: Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158
references: 15361314
references: J Health Econ. 1997 Feb;16(1):33-64
references: 10167344
references: Value Health. 2003 Jan-Feb;6(1):9-17
references: 12535234
references: JAMA. 2010 Nov 3;304(17):1936-43
references: 21045100
references: BMC Neurol. 2009 Jan 06;9:1
references: 19126193
references: Neurology. 1995 Jul;45(7):1277-85
references: 7617182
references: Pharmacoeconomics. 2010;28(10):969-76
references: 20831305
references: Pharmacoeconomics. 2010;28(10):799-811
references: 20831288
references: J Manag Care Pharm. 2007 Apr;13(3):245-61
references: 17407391
references: Ann Neurol. 1996 Mar;39(3):285-94
references: 8602746
references: BMJ. 2006 Mar 25;332(7543):699-703
references: 16495332
references: Med Decis Making. 2010 Jul-Aug;30(4):E14-27
references: 20551473
references: Pharmacoeconomics. 2010;28(9):699-709
references: 20629473
references: J Interferon Cytokine Res. 1999 Nov;19(11):1257-64
references: 10574618
references: Neurology. 1999 Jan 1;52(1):215-6
references: 9921887
references: Pharmacoeconomics. 2000 May;17(5):461-77
references: 10977388
references: Lancet. 2002 Apr 27;359(9316):1453-60
references: 11988242
references: J Cardiovasc Electrophysiol. 2013 Jan;24(1):66-74
references: 22913474
references: Neurology. 2011 Jul 26;77(4):317-8
references: 21775745
references: Mult Scler. 2005 Oct;11(5):542-51
references: 16193892
references: Annu Rev Public Health. 1998;19:17-34
references: 9611610
references: Lancet. 1998 Nov 7;352(9139):1498-504
references: 9820297
references: Neurology. 2000 Jun 13;54(11):2055-60
references: 10851362
references: Neurology. 2008 Jul 29;71(5):357-64
references: 18663181
references: J Manag Care Pharm. 2011 Jul-Aug;17(6):463-8
references: 21787032
references: Neurology. 1997 Aug;49(2):358-63
references: 9270562
references: Pharmacoeconomics. 2010;28(10):931-4
references: 20831301
references: Pharmacoeconomics. 2010;28(10):855-65
references: 20831293